Nvwm LLC Invests $90,000 in Exact Sciences Corporation $EXAS

Nvwm LLC acquired a new position in Exact Sciences Corporation (NASDAQ:EXAS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,700 shares of the medical research company’s stock, valued at approximately $90,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC boosted its position in Exact Sciences by 2,804.8% during the first quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock valued at $26,000 after buying an additional 589 shares during the period. Bessemer Group Inc. boosted its holdings in Exact Sciences by 1,980.6% during the 2nd quarter. Bessemer Group Inc. now owns 645 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 614 shares during the period. National Pension Service grew its position in Exact Sciences by 75.1% during the 1st quarter. National Pension Service now owns 681 shares of the medical research company’s stock worth $29,000 after acquiring an additional 292 shares during the last quarter. SVB Wealth LLC bought a new position in Exact Sciences during the 1st quarter worth approximately $30,000. Finally, Banque Cantonale Vaudoise bought a new stake in Exact Sciences in the first quarter valued at approximately $34,000. Institutional investors own 88.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on EXAS shares. Craig Hallum increased their price objective on Exact Sciences from $65.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, September 11th. Benchmark lifted their target price on shares of Exact Sciences from $60.00 to $75.00 and gave the stock a “buy” rating in a research note on Tuesday. Guggenheim increased their price target on shares of Exact Sciences from $70.00 to $75.00 and gave the company a “buy” rating in a research report on Tuesday. Robert W. Baird raised their price target on shares of Exact Sciences from $72.00 to $88.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Barclays boosted their price objective on shares of Exact Sciences from $65.00 to $77.00 and gave the company an “overweight” rating in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Exact Sciences has a consensus rating of “Moderate Buy” and an average price target of $73.44.

Insider Activity

In other Exact Sciences news, Director James Edward Doyle sold 2,000 shares of Exact Sciences stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $60.00, for a total transaction of $120,000.00. Following the sale, the director directly owned 57,962 shares of the company’s stock, valued at approximately $3,477,720. The trade was a 3.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Brian Baranick sold 2,858 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $70.08, for a total value of $200,288.64. Following the transaction, the executive vice president owned 22,368 shares in the company, valued at $1,567,549.44. This trade represents a 11.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,343 shares of company stock valued at $382,688 over the last 90 days. 1.20% of the stock is currently owned by company insiders.

Exact Sciences Stock Down 1.5%

Shares of Exact Sciences stock opened at $66.18 on Friday. The company has a current ratio of 2.89, a quick ratio of 2.56 and a debt-to-equity ratio of 0.94. Exact Sciences Corporation has a 12-month low of $38.81 and a 12-month high of $72.81. The company has a market cap of $12.53 billion, a P/E ratio of -12.19, a PEG ratio of 5.56 and a beta of 1.34. The company’s fifty day simple moving average is $58.09 and its two-hundred day simple moving average is $53.40.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Monday, November 3rd. The medical research company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.13 by $0.11. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The firm had revenue of $850.74 million during the quarter, compared to analysts’ expectations of $810.42 million. During the same period last year, the company posted ($0.21) EPS. The company’s quarterly revenue was up 20.0% compared to the same quarter last year. Exact Sciences has set its FY 2025 guidance at EPS. Research analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.